CN103041266B - Medicine for treating pediatric postoperative pneumonia - Google Patents
Medicine for treating pediatric postoperative pneumonia Download PDFInfo
- Publication number
- CN103041266B CN103041266B CN201310027046.8A CN201310027046A CN103041266B CN 103041266 B CN103041266 B CN 103041266B CN 201310027046 A CN201310027046 A CN 201310027046A CN 103041266 B CN103041266 B CN 103041266B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- pneumonia
- pediatric
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a medicine for treating pediatric postoperative pneumonia, which is used for solving a treatment problem of pediatric postoperative pneumonia. The medicine is characterized by being formed by processing various traditional Chinese medicines and being prepared from the following raw materials in parts by weight: 10-20 parts of chuanposhi, 8-15 parts of tuber fleeceflower stems, 8-15 parts of herba aistolochiae, 6-10 parts of sunglo, 6-10 parts of fagopyrum dibotrys stems and leaves, 8-15 parts of semen cuscutae, 6-10 parts of hinese starjasmine stems, 8-15 parts of vandenboschia auriculata and 3-6 parts of alpinia japonica. According to the clinical experiment, the medicine has characteristics of a good curative effect and high safety in treating the pediatric postoperative pneumonia, and is worthy of being popularized and applied clinically.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to treat the medicine of pneumonia after pediatric operation.
Background technology
After pediatric operation, pneumonia refers to various types of pulmonary parenchyma inflammation that patient is caused by pathogen such as antibacterial, funguses in 2 weeks after operation 24 h, postoperatively first there is the complication such as respiratory failure and give tracheal intubation, then just there is pneumonia person, be attributed to respirator pneumonia, do not belong to pneumonia category after pediatric operation.Due to children's's special body constitution, in operation, easily occur that afterwards pulmonary ventilation is not enough, diaphram is movable poor, and coughre flex is impaired or suppressed, and bronchospasm and dehydration all can cause that bronchial secretion is detained, and cause segmental atelectasis, and then pulmonary infection occurs.This type of infection rate of chest or abdominal postoperative is higher, and the pneumonia incidence rate after inhalation anesthesia and spinal anesthesia is equal, and the postoperative infection of local anesthesia or intravenous anesthesia only accounts for 10%.
Previously research shows, compares with same bacterial other pneumonia, and chest X-ray shows that lung infiltrates focus and/or pulmonary atelectasis is more obvious, and severe one also has the evidence with pulmonary infarction and infarction.And bacteriology checking shows gram negative bacilli, staphylococcus aureus, the mixing situation of streptococcus pneumoniae and hemophilus influenza or these bacterium is many.
After clinical treatment pediatric operation, pneumonia is as good as with common pulmonary infection substantially at present, according to bacteriology checking and drug sensitive experiment, selects applicable antibiotic, and the traditional Chinese medical science is also so, multiplex heat-clearing and toxic substances removing medicine, lung heat clearing row carbuncle.But after pediatric operation, pneumonia has greatly different from pneumonia in pathogenesis, antibacterial or mycoplasma invasion and attack are only performances thereupon, real pathogenic basis is " pulmonary ventilation is not enough; diaphram is movable poor, and coughre flex is impaired or suppressed, bronchospasm and dehydration ", for pathogenic microorganism, only treat and take stopgap measures merely, the Primary factors of this pulmonary does not improve, once drug withdrawal can be recurred.And in the situation that segmental atelectasis, bronchial secretion are detained, remove pathogenic microorganism, need to increase the dosage that antibiotic is used, Liver and kidney metabolism burden after increase pediatric operation.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, and the medicine of pneumonia after the sure treatment pediatric operation of a kind of curative effect is provided.
The technical scheme that the present invention solves its technical problem is: a kind of medicine for the treatment of pneumonia after pediatric operation, its composition of raw materials and weight proportion are: 10 ~ 20 parts of Radix Cudraniaes, 8 ~ 15 parts of Caulis Polygoni Multiflori, 8 ~ 15 parts of Herba Alyxiae Sinensiss, 6 ~ 10 parts of Usneas, 6 ~ 10 parts of Rhizoma Fagopyri Dibotryis stem and leaf, 8 ~ 15 parts of Semen Cuscutae, 6 ~ 10 parts of Caulis Trachelospermis, 8 ~ 15 parts of Trichomanes auriculatum Bl-Cop, 3 ~ 6 parts of Alpinia japonica (Thunb.) Miq.s.
Its optimum weight proportioning is: 15 parts of Radix Cudraniaes, 10 parts of Caulis Polygoni Multiflori, 10 parts of Herba Alyxiae Sinensiss, 8 parts of Usneas, 8 parts of Rhizoma Fagopyri Dibotryis stem and leaf, 10 parts of Semen Cuscutae, 8 parts of Caulis Trachelospermis, 10 parts of Trichomanes auriculatum Bl-Cop, 5 parts of Alpinia japonica (Thunb.) Miq.s.
Wherein said: Radix Cudraniae, for Moraceae three-bristle cudrania platymiscium cudrania cochinchinensis Cudrania cochin chinensis (Lour.) Kudo et Masam., is used as medicine with root.Property mildly bitter flavor, flat.Return lung, Liver Channel.Merit can relieving cough and resolving phlegm, expelling wind and removing dampness, eliminating stasis to stop pain.
Caulis Polygoni Multiflori is rattan or the leaf bine stem of polygonum multiflorum thunb Polygonum multiflorum Thunb..Sweet, micro-hardship, property is flat.GUIXIN, Liver Channel.Merit can tranquilizing by nourishing the heart, dispels the wind, and dredging collateral.
Herba Alyxiae Sinensis is herb and the root of apocynaceae plant chain pearl rattan.Toil, flat.Enter lung, liver, spleen three warps.Merit can expelling wind and removing dampness, promoting blood circulation to remove obstruction in the collateral.
Usnea is the thallus (thallus) of Usneaceae Usnea plant USNEA Usnea diffracta (female trailing plants, Herba Cucubali) Usnea diffracta Vain. or Usnea Longissima (Scolopendra Usnea, Herba Stellariae Alsines) U. longissima Ach..Nature and flavor are sweet, flat.Return lung; Liver; Kidney channel.Merit can heat-clearing and toxic substances removing, hemostasia and promoting granulation, and pain relieving, liver heat removing and eyesight improving, moves back nebula.
Rhizoma Fagopyri Dibotryis stem and leaf is the stem and leaf of polygonaceae plant Rhizoma Fagopyri Dibotryis Fagopyrum dibotrys (D.Don) Hara.Nature and flavor are bitter, pungent, cool in nature.Return lung, spleen, Liver Channel.Merit can heat-clearing and toxic substances removing, invigorating spleen to remove dampness, dispelling wind and removing obstruction in the collateral.
Semen Cuscutae is the dry mature seed of convolvulus cuscuta plant Cuscuta chinensis Lam..Nature and flavor are sweet, temperature.Return liver,kidney,spleen warp.Merit can nourishing the liver and kidney, and controlling nocturnal emission with astringent drugs reducing urination is antiabortive, improving eyesight, antidiarrheal.
Caulis Trachelospermi is the dry zone leaf rattan of apocynaceae plant trachelospermum jasminoide Trachelospermum jasminoides (Lindl.) Lem..Hardship, is slightly cold.GUIXIN, liver, kidney channel.Merit can dispelling wind and removing obstruction in the collateral, removing heat from blood detumescence.
Trichomanes auriculatum Bl-Cop is the herb of hymenophyllaceae plant Trichomanes auriculatum Bl-Cop Trichomanes uriculatum Bl..Property mildly bitter flavor; Flat.Return Liver Channel.Merit can promoting regeneration of the tissue and arresting bleeding.
Alpinia japonica (Thunb.) Miq., for Zingiberaceae Alpinia plants Alpinia japonica (Thunb.) Miq. Alpinia japonica Miq., is used as medicine with root stock.Nature and flavor are pungent, warm.Return lung, spleen, Liver Channel.Merit can dispelling wind and removing obstruction in the collateral, regulating QI to relieve pain.
Composition principle: after pediatric operation, pneumonia is different from common pulmonary infection, antibacterial or mycoplasma invasion and attack are only performances thereupon, real pathogenic basis is " pulmonary ventilation is not enough; diaphram is movable poor, and coughre flex is impaired or suppressed, bronchospasm and dehydration ", for pathogenic microorganism, only treat and take stopgap measures merely, the Primary factors of this pulmonary does not improve, once drug withdrawal can be recurred.So for this pathologic basis, the rule for the treatment of should be and " solves pulmonary ventilation not enough, increase lung ventilation amount; Dispel bronchial secretion and be detained, improve bronchospasm and dehydration ".Reduce medicament categories and dosage simultaneously as far as possible, do not increase Liver and kidney metabolism burden after pediatric operation.
The present invention compared with the prior art, has following characteristics.
1, prescription is unique: in side, get Radix Cudraniae, Caulis Polygoni Multiflori is monarch, described Radix Cudraniae coordinates with Caulis Polygoni Multiflori, for pneumonia after pediatric operation, can pass through dredging collateral dissipating blood stasis alleviating pain, overcomes the pulmonary ventilation deficiency that pain causes, and diaphram activity is poor; And Radix Cudraniae can solve bronchial secretion by reducing phlegm and be detained, and helps lend some impetus to sputum thinning, and can be as other apophlegmatisants reactive stimulation bronchus, can not increase the weight of bronchus dehydration and reflex cough's expectoration; And the dredging collateral of Caulis Polygoni Multiflori is done, in order to mend as first, to take into account tranquilizing by nourishing the heart, reinforcement and elimination in combination, the young positive children's's body constitution of the most suitable young the moon, postoperative pneumonia is used.
2, in side, get Herba Alyxiae Sinensis, Usnea is minister, Herba Alyxiae Sinensis expelling wind and removing dampness, promoting blood circulation to remove obstruction in the collateral, can enter lung, Liver Channel, the capable thoracic wall of Liver Channel, Herba Alyxiae Sinensis can specific alleviation pleural irritation symptom, contributes to increase lung ventilation amount; And inventor for many years Clinical and experimental study show, the spasm that Usnea can antagonism barium chloride, acetylcholine causes, have bronchus relexation, 10 mgs/kg of usnic acid sodium of anesthetized cat intravenous injection, can strengthen rapidly and significantly its breathing, the raising ventilation of long period.
3, supplementary drug thing is fewer but better, Rhizoma Fagopyri Dibotryis stem and leaf heat-clearing and toxic substances removing and dredging collateral; Semen Cuscutae nourishing the liver and kidney, solidifying gas under, and have sun in Semen Cuscutae the moon, keep and can walk, different absolutely with the greasy stagnant person of being partial to of all medicines of other YIN nourishing; Caulis Trachelospermi enters the capable thoracic wall of Liver Channel, helps Herba Alyxiae Sinensis dredging collateral removing heat from blood; The Trichomanes auriculatum Bl-Cop promoting blood circulation and stopping pain of enriching blood.
4, get Alpinia japonica (Thunb.) Miq. using corrigent simply, Alpinia japonica (Thunb.) Miq. nature and flavor are pungent, warm, pungent and wander away, and Wen Erqi is capable, in one cold and cool medicine, gets the meaning of slightly activating yang.
5, the thing homogeneous medicine multiple-effect of getting it filled in side, contributes to reduce medicament categories and consumption, does not increase Liver and kidney burden after pediatric operation.
6, medicine material consumption of the present invention is groped in a large number to sum up through inventor and is drawn, each raw material consumption is for all to have good curative effect in following weight parts scope.
The specific embodiment
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, crude drug weight proportion: Radix Cudraniae 10g, Caulis Polygoni Multiflori 8g, Herba Alyxiae Sinensis 8g, Usnea 6g, Rhizoma Fagopyri Dibotryis stem and leaf 6g, Semen Cuscutae 8g, Caulis Trachelospermi 6g, Trichomanes auriculatum Bl-Cop 8g, Alpinia japonica (Thunb.) Miq. 3g.
Embodiment 2, crude drug weight proportion: Radix Cudraniae 20g, Caulis Polygoni Multiflori 15g, Herba Alyxiae Sinensis 15g, Usnea 10g, Rhizoma Fagopyri Dibotryis stem and leaf 10g, Semen Cuscutae 15g, Caulis Trachelospermi 10g, Trichomanes auriculatum Bl-Cop 15g, Alpinia japonica (Thunb.) Miq. 6g.
Embodiment 3, crude drug weight proportion: Radix Cudraniae 15g, Caulis Polygoni Multiflori 10g, Herba Alyxiae Sinensis 10g, Usnea 8g, Rhizoma Fagopyri Dibotryis stem and leaf 8g, Semen Cuscutae 10g, Caulis Trachelospermi 8g, Trichomanes auriculatum Bl-Cop 10g, Alpinia japonica (Thunb.) Miq. 5g.
During use, Chinese medicine Radix Cudraniae of the present invention, Caulis Polygoni Multiflori, Herba Alyxiae Sinensis, Usnea, Rhizoma Fagopyri Dibotryis stem and leaf, Semen Cuscutae, Caulis Trachelospermi, Alpinia japonica (Thunb.) Miq., Trichomanes auriculatum Bl-Cop are decocted with water to twice, merging filtrate, a minute morning and evening takes.4 following children of one full year of life get above-mentioned dosage 1/4 and are advisable, and 4 ~ 12 one full year of life got above-mentioned dosage 1/2 and are advisable, and 12 above children of one full year of life get full dosage.
Effective combination of said medicine, coordinates mutually, can effectively reach the object of pneumonia after treatment pediatric operation, and side effect is less.The above results is that clinical data fully proves, interrelated data is as follows, and wherein drugs use is the crude drug weight proportion in embodiment 3.
1 object and method.
1.1 object.
1.1.1 inclusive criteria: be pneumonia 80 examples after in January, 2008 ~ 2012 year December pediatric operation, patient all meets U.S.'s disease prevention and control centre about the diagnostic criteria of " postoperative pneumonia ", the equal nutriture of each case is good, and blood glucose, blood fat and hepatic and renal function are all in normal range.The diagnostic criteria of " postoperative pneumonia " is: performs the operation after 24 h in 2 weeks and there is no the patient of intubate, and (1) chest health check-up discovery rale or dull percussion note, and possess following any one person: 1. recently occur that purulent sputum or sputum character change; 2. blood cultivation is isolated microorganism; 3. in trachea, sucking-off liquid, bronchial brushing or biopsy specimen, isolate pathogen; (2) chest X-ray prompting have recently occur or be lung infiltration, consolidation, cavity, the hydrothorax that carries out sexual development, and possess following any one person: 1. recently occur that purulent sputum or sputum character change; 2. blood cultivation is isolated microorganism; 3. in trachea, sucking-off liquid, bronchial brushing or biopsy specimen, isolate pathogen; 4. be separated in virus or respiratory secretions and virus antigen detected; 5. the monoclonal antibody titre (IgM) of pathogen reaches and diagnoses level level or paired sera sample (IgG) to increase 4 times; 6. the histopathology evidence of pneumonia.
1.2 method.
1.2.1 research method: 80 routine patients, are divided into 2 groups, treatment group 40 examples, male 21 examples, female's 19 examples, age average (7.25 ± 1.73) year at random; Matched group 40 examples, male 23 examples, female's 17 examples, age average (6.95 ± 2.52) year.Two groups of sexes, age and state of an illness aspect difference not statistically significants (P>0.05).Matched group is chosen antibiotic therapy according to bacteriology checking result, treatment group adds by the use that is decocted in water for oral dose of the crude drug weight proportion in embodiment 3 on the therapeutic scheme of matched group, 4 following children of one full year of life get above-mentioned dosage 1/4 and are advisable, 4 ~ 12 one full year of life got above-mentioned dosage 1/2 and are advisable, and 12 above children of one full year of life get full dosage.
1.2.2 safety evaluatio: all carry out the monitorings such as blood, urine, stool routine, liver, renal function, electrocardiogram before and after medication.
1.2.3 statistical analysis: carry out statistical analysis with SPSS 11.0, P< 0.05 indicates significant.
2 results.
Different time sections Comparison of therapeutic in 2.1 liang of group groups: after 2 groups of patient treatments, symptom all has clear improvement.In two groups of groups, relatively treat 1w and all have statistical significance (treatment group χ with the difference that treatment 2w total effective rate exists
2=4.163, P=0.046; Matched group χ
2=5.166, P=0.023).
Different time sections Comparison of therapeutic between 2.2 liang of group groups: after treatment 1w, the cure-remarkable-effectiveness rate for the treatment of group and matched group is respectively 87.50%(35/40) and 57.50%(23/40), after treatment 2w, cure-remarkable-effectiveness rate is 92.50%(37/40) and 90.00%(36/40), after treatment 1w, the cure-remarkable-effectiveness rate for the treatment of group is apparently higher than matched group (P<0.05).
2.3 untoward reaction: patient's vital sign (blood pressure, heart rate, body temperature, breathing), physical examination, blood biochemical analysis, electrocardiogram and routine urinalysis Non Apparent Abnormality during treating.
3. conclusion.
This result of study shows, the present invention can effectively treat pneumonia after pediatric operation, can improve pneumonia patient symptom after pediatric operation, and more existing therapeutic scheme is more early effective, cures sooner.Clinical relevant lab testing (comprising electrocardiogram) and vital sign have no obvious change, and without obviously side reaction, clinic is selected.
Claims (2)
1. a medicine for the treatment of pneumonia after pediatric operation, it is characterized in that being processed by plurality of Chinese, its composition of raw materials and weight proportion are: 10 ~ 20 parts of Radix Cudraniaes, 8 ~ 15 parts of Caulis Polygoni Multiflori, 8 ~ 15 parts of Herba Alyxiae Sinensiss, 6 ~ 10 parts of Usneas, 6 ~ 10 parts of Rhizoma Fagopyri Dibotryis stem and leaf, 8 ~ 15 parts of Semen Cuscutae, 6 ~ 10 parts of Caulis Trachelospermis, 8 ~ 15 parts of Trichomanes auriculatum Bl-Cop, 3 ~ 6 parts of Alpinia japonica (Thunb.) Miq.s.
2. a kind of medicine for the treatment of pneumonia after pediatric operation according to claim 1, is characterized in that its weight proportion is: 15 parts of Radix Cudraniaes, 10 parts of Caulis Polygoni Multiflori, 10 parts of Herba Alyxiae Sinensiss, 8 parts of Usneas, 8 parts of Rhizoma Fagopyri Dibotryis stem and leaf, 10 parts of Semen Cuscutae, 8 parts of Caulis Trachelospermis, 10 parts of Trichomanes auriculatum Bl-Cop, 5 parts of Alpinia japonica (Thunb.) Miq.s.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310027046.8A CN103041266B (en) | 2013-01-25 | 2013-01-25 | Medicine for treating pediatric postoperative pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310027046.8A CN103041266B (en) | 2013-01-25 | 2013-01-25 | Medicine for treating pediatric postoperative pneumonia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103041266A CN103041266A (en) | 2013-04-17 |
| CN103041266B true CN103041266B (en) | 2014-01-29 |
Family
ID=48054277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310027046.8A Expired - Fee Related CN103041266B (en) | 2013-01-25 | 2013-01-25 | Medicine for treating pediatric postoperative pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103041266B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1530133A (en) * | 2003-03-12 | 2004-09-22 | 陈见民 | Medicine for treating lung cancer |
| CN1586526A (en) * | 2004-07-29 | 2005-03-02 | 邢乐道 | Compound medicine for treating tuberculosis and its preparing method |
| CN102579664A (en) * | 2012-03-05 | 2012-07-18 | 王敬祥 | Traditional Chinese medicine for quick healing of postoperative incision |
| CN102755421A (en) * | 2012-08-01 | 2012-10-31 | 叙永县中医医院 | Traditional Chinese medicine for preventing pulmonary embolism after operation |
-
2013
- 2013-01-25 CN CN201310027046.8A patent/CN103041266B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1530133A (en) * | 2003-03-12 | 2004-09-22 | 陈见民 | Medicine for treating lung cancer |
| CN1586526A (en) * | 2004-07-29 | 2005-03-02 | 邢乐道 | Compound medicine for treating tuberculosis and its preparing method |
| CN102579664A (en) * | 2012-03-05 | 2012-07-18 | 王敬祥 | Traditional Chinese medicine for quick healing of postoperative incision |
| CN102755421A (en) * | 2012-08-01 | 2012-10-31 | 叙永县中医医院 | Traditional Chinese medicine for preventing pulmonary embolism after operation |
Non-Patent Citations (4)
| Title |
|---|
| "中药治疗肺移植术后1例体会";赵玉霞等;《中国医学工程》;20110831;第19卷(第8期);第131-132、134页 * |
| "自制中药舒肺散在治疗肺癌术后肺不张中的疗效观察";倪建林等;《中医中药》;20111130;第18卷(第31期);第108-109页 * |
| 倪建林等."自制中药舒肺散在治疗肺癌术后肺不张中的疗效观察".《中医中药》.2011,第18卷(第31期),第108-109页. |
| 赵玉霞等."中药治疗肺移植术后1例体会".《中国医学工程》.2011,第19卷(第8期),第131-132、134页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103041266A (en) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111388582B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| CN111773308A (en) | Traditional Chinese medicine composition of 'lung-ventilating and toxin-expelling decoction' for preventing and treating new coronary pneumonia and preparation method | |
| CN103520395B (en) | Traditional Chinese medicine composition for treating lung cancer | |
| CN101579186A (en) | Pharmaceutical rhinitis pillow for external use and treating wind-heat rhinitis | |
| CN102716261B (en) | Wind-damp expelling traditional Chinese medicine powder | |
| CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN104306793B (en) | A kind of Chinese medicine preparation for treating lobar pneumonia | |
| CN105497723A (en) | Traditional Chinese medicine preparation for treating bacterial pneumonia and preparation method thereof | |
| CN102178892A (en) | Chinese medicinal composition for treating depression | |
| CN101062255A (en) | Decoction for treating asthma and so on | |
| CN103041266B (en) | Medicine for treating pediatric postoperative pneumonia | |
| CN103041269B (en) | A kind of Chinese medicine for the treatment of postoperative pneumonia | |
| CN103041268B (en) | Medicament for treating post-traumatic pneumonia | |
| CN109793852A (en) | A kind of cough-relieving, resolving sputum and the Chinese medicine composition relievingd asthma | |
| CN104474407A (en) | Traditional Chinese medicine preparation for treating pertussis | |
| CN105194165B (en) | Traditional Chinese medicine used for treating infection of urinary system and preparation method thereof | |
| CN108653552B (en) | Traditional Chinese medicine for clearing lung and relieving cough | |
| CN105687684A (en) | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease | |
| CN106110244A (en) | Powder for relieving cough and asthma | |
| CN106474405A (en) | A kind of Chinese medicine formula treating cough | |
| CN1059125C (en) | Manzhiyu traditional Chinese medicine preparation | |
| CN105079215A (en) | Medicine composition for treating diabetic foot ulcer | |
| CN104257875A (en) | Externally-applied traditional Chinese medicine composition for nursing acute mastitis of women | |
| CN104721386B (en) | A kind of Traditional Chinese medicine external patch and preparation method thereof for treating asthenic cold type cough and asthma | |
| CN111514215A (en) | Traditional Chinese medicine prescription for treating upper respiratory tract infection and viral pneumonia and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140129 Termination date: 20150125 |
|
| EXPY | Termination of patent right or utility model |